The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Johnathan Whetstine to lead Cancer Epigenetics Program at Fox Chase

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Johnathan Whetstine was named program leader of the Cancer Epigenetics Program at Fox Chase Cancer Center.

Whetstine comes to Fox Chase from Massachusetts General Hospital Cancer Center and Harvard Medical School, where he served as vice chair of the Epigenetics Program. He also held appointments as associate geneticist and associate professor in the department of medicine.

Whetstine’s work has focused on understanding tumor heterogeneity and drug response. He holds the scholar award from the Leukemia & Lymphoma Society and an NIH R01 grant, as well as funding from the American Lung Association, Alex Lemonade Stand Foundation and AstraZeneca.

The new Cancer Epigenetics Program Whetstine will lead has basic, translational, and clinical research components.

Whetstine will begin his work at Fox Chase on Dec. 1.

Table of Contents

YOU MAY BE INTERESTED IN

PodcastThe Directors

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.
By Katie Goldberg
Capitol Hill

Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges

In back-to-back congressional hearings earlier this week, HHS Secretary Robert F. Kennedy Jr. said that the massive staff and budget cuts over which he has presided during his nearly four months on the job as well as even bigger cuts still looming on the horizon are a part of a single plan.
By Jacquelyn Cobb and Claire Marie Porter
Clinical

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

Natalie Phelps, a 43-year-old mother of two, has stage 4 colorectal cancer. She has become a central figure in the controversy over the dysfunction the Trump administration’s RIFs and budget cuts have brought to NIH. 
By Jacquelyn Cobb
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account